Xinhua Pharmaceutical released its 2026 interim report. Total operating revenue was 4.358 billion yuan, down 6.06% year-on-year. Net profit attributable to the parent company was 149 million yuan, down 33.35% year-on-year. Net cash inflow from operating activities was 161 million yuan, down 31.40% year-on-year. The company's asset-liability ratio was 39.32%, gross margin was 19.16%, ROE was 2.83%, and diluted earnings per share was 0.21 yuan. Total asset turnover was 0.48 times, and inventory turnover was 2.70 times. The number of shareholders was 79,900, and the top ten shareholders held 63.62% of the total share capital.
Shandong Xinhua Pharmaceutical Co LtdNet profit down 33.35% year-on-year in interim report
